• Investigation of the anti-cancer effects of rosemary (Rosmarinus Officinalis L.) extract in human breast and prostate cancer cells

      Jaglanian, Alina; Applied Health Sciences Program
      Breast and prostate cancer are the most frequently diagnosed cancers in women and men respetively, in North America. Triple-negative breast cancer (TNBC) cells do not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER-2). TNBC accounts for 15% of all breast cancer cases, is aggressive in nature, and is characterized by resistance to chemo and radiotherapy thus, finding new approaches to inhibit it are urgently needed. Similarly, prostate cancer is typically characterized by the expression of androgen receptor (AR) and prostate-specific antigen (PSA). Prostate cancer that is AR positive can be treated with hormonal therapy. In contrast, AR negative prostate cancer is more aggressive and does not respond to hormone therapy, thus new approaches, including identifying specific signaling molecules that are overactivated and could be targeted, are required to effectively treat this subtype of prostate cancer. Rosemary extract (RE) has been shown to have anti-cancer properties in vitro and in vivo. However, limited evidence exists regarding its effect on triple-negative breast cancer and AR negative prostate cancer. In this study, we examined the effects of RE on triple-negative breast cancer cell (MDA-MB-231) and androgen insensitive prostate cancer cell (PC-3) proliferation, survival/apoptosis, and migration. In addition, we investigated the effect of RE treatment on key signaling molecules involved in cancer cell proliferation and survival.